Sophia Genetics SA (SOPH) - Net Assets
Based on the latest financial reports, Sophia Genetics SA (SOPH) has net assets worth $60.69 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($163.46 Million) and total liabilities ($102.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SOPH asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $60.69 Million |
| % of Total Assets | 37.13% |
| Annual Growth Rate | 9.88% |
| 5-Year Change | -4.0% |
| 10-Year Change | N/A |
| Growth Volatility | 150.71 |
Sophia Genetics SA - Net Assets Trend (2018–2024)
This chart illustrates how Sophia Genetics SA's net assets have evolved over time, based on quarterly financial data. Also explore Sophia Genetics SA assets under control for the complete picture of this company's asset base.
Annual Net Assets for Sophia Genetics SA (2018–2024)
The table below shows the annual net assets of Sophia Genetics SA from 2018 to 2024. For live valuation and market cap data, see Sophia Genetics SA stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $96.49 Million | -36.29% |
| 2023-12-31 | $151.44 Million | -24.33% |
| 2022-12-31 | $200.13 Million | -27.33% |
| 2021-12-31 | $275.40 Million | +174.00% |
| 2020-12-31 | $100.51 Million | +351.67% |
| 2019-12-31 | $22.25 Million | -59.41% |
| 2018-12-31 | $54.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sophia Genetics SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37572800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.19 Million | 4.34% |
| Other Comprehensive Income | $61.04 Million | 63.26% |
| Other Components | $471.54 Million | 488.70% |
| Total Equity | $96.49 Million | 100.00% |
Sophia Genetics SA Competitors by Market Cap
The table below lists competitors of Sophia Genetics SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sandhar Technologies Limited
NSE:SANDHAR
|
$321.60 Million |
|
Iljin Holdings
KO:015860
|
$321.61 Million |
|
Jay Mart Public Company Limited
BK:JMART
|
$321.70 Million |
|
Wuhan Golden Laser Co Ltd
SHE:300220
|
$321.70 Million |
|
Goody Science & Technology Co Ltd
SHE:002694
|
$321.59 Million |
|
Energy One Ltd
AU:EOL
|
$321.55 Million |
|
Peach Property Group AG
SW:PEAN
|
$321.55 Million |
|
PI Advanced Materials Co. Ltd
KQ:178920
|
$321.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sophia Genetics SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 151,442,000 to 96,490,000, a change of -54,952,000 (-36.3%).
- Net loss of 62,493,000 reduced equity.
- Other comprehensive income increased equity by 7,059,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-62.49 Million | -64.77% |
| Other Comprehensive Income | $7.06 Million | +7.32% |
| Other Changes | $482.00K | +0.5% |
| Total Change | $- | -36.29% |
Book Value vs Market Value Analysis
This analysis compares Sophia Genetics SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.63x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 6.15x to 3.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.87 | $5.32 | x |
| 2019-12-31 | $0.35 | $5.32 | x |
| 2020-12-31 | $2.09 | $5.32 | x |
| 2021-12-31 | $4.98 | $5.32 | x |
| 2022-12-31 | $3.12 | $5.32 | x |
| 2023-12-31 | $2.34 | $5.32 | x |
| 2024-12-31 | $1.47 | $5.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sophia Genetics SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -64.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -95.89%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 1.61x
- Recent ROE (-64.77%) is below the historical average (-63.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -151.85% | -133.23% | 0.49x | 2.32x | $-36.02 Million |
| 2020 | -39.14% | -138.52% | 0.21x | 1.31x | $-49.39 Million |
| 2021 | -26.75% | -182.14% | 0.13x | 1.16x | $-101.22 Million |
| 2022 | -43.70% | -183.87% | 0.20x | 1.22x | $-107.46 Million |
| 2023 | -52.15% | -126.63% | 0.30x | 1.36x | $-94.13 Million |
| 2024 | -64.77% | -95.89% | 0.42x | 1.61x | $-72.14 Million |
Industry Comparison
This section compares Sophia Genetics SA's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $363,436,353
- Average return on equity (ROE) among peers: -160.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sophia Genetics SA (SOPH) | $60.69 Million | -151.85% | 1.69x | $321.60 Million |
| Aclarion Inc (ACON) | $2.23 Million | -317.55% | 0.31x | $1.99 Million |
| American Well Corp (AMWL) | $480.19 Million | -140.60% | 0.23x | $90.87 Million |
| Heartbeam Inc (BEAT) | $-26.87 Million | 0.00% | 0.00x | $30.38 Million |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $-3.06 Million | 0.00% | 0.00x | $6.51 Million |
| BrightSpring Health Services, Inc. Common Stock (BTSG) | $612.55 Million | -25.24% | 8.03x | $8.82 Billion |
| Carlsmed, Inc. Common Stock (CARL) | $-70.63 Million | 0.00% | 0.00x | $253.42 Million |
| CareCloud Inc. (CCLD) | $101.25 Million | -8.70% | 0.36x | $117.28 Million |
| Certara Inc (CERT) | $492.05 Million | -1.81% | 1.11x | $983.48 Million |
| CareMax Inc (CMAX) | $61.44 Million | -1112.15% | 9.14x | $381.50 |
| Claritev Corporation (CTEV) | $1.99 Billion | 0.49% | 3.21x | $277.75 Million |
About Sophia Genetics SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutic… Read more